HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Holger Jensen Selected Research

Astatine-211

1/2021Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer.
11/2019Towards elucidating the radiochemistry of astatine - Behavior in chloroform.
1/2019Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
3/2016Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates.
7/2015Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.
2/2015Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies.
8/2014Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
7/2014Alpha particle induced DNA damage and repair in normal cultured thyrocytes of different proliferation status.
10/2007Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Holger Jensen Research Topics

Disease

29Neoplasms (Cancer)
01/2021 - 09/2003
17Ovarian Neoplasms (Ovarian Cancer)
01/2021 - 09/2003
6Carcinoma (Carcinomatosis)
01/2017 - 10/2007
5Ascites
03/2013 - 11/2005
3Body Weight (Weight, Body)
02/2020 - 04/2013
2Neoplasm Metastasis (Metastasis)
02/2020 - 08/2014
2Residual Neoplasm
02/2020 - 11/2015
1Prostatic Neoplasms (Prostate Cancer)
02/2020
1Fatigue
01/2019
1Ovarian Epithelial Carcinoma
01/2019
1Intestinal Perforation
01/2019
1Neoplasm Micrometastasis
08/2013
1Weight Loss (Weight Reduction)
04/2013
1Disease Progression
03/2013
1Colorectal Neoplasms (Colorectal Cancer)
08/2007

Drug/Important Bio-Agent (IBA)

9Astatine-211IBA
01/2021 - 10/2007
9Monoclonal AntibodiesIBA
01/2019 - 09/2003
7211At-labeled monoclonal antibody MX35IBA
01/2021 - 08/2006
6AntibodiesIBA
01/2021 - 09/2003
3AntigensIBA
02/2020 - 08/2007
3AstatineIBA
03/2016 - 12/2009
3Immunoconjugates (Immunoconjugate)IBA
03/2016 - 12/2005
3Biological ProductsIBA
07/2014 - 12/2005
2Radioisotopes (Radionuclides)IBA
02/2015 - 04/2013
2EpitopesIBA
01/2015 - 09/2003
1Rituximab (Mabthera)FDA Link
01/2021
1farletuzumabIBA
01/2021
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
02/2020
1Indicators and Reagents (Reagents)IBA
01/2019
1TinIBA
03/2016
1Neoplasm Antigens (Tumor Antigens)IBA
01/2015
1BR96 monoclonal antibodyIBA
08/2014
1Lutetium-177IBA
08/2014
1HalogensIBA
08/2014
1Reducing AgentsIBA
08/2014
1Eosine Yellowish-(YS) (Eosin)IBA
08/2013
1Hematoxylin (Haematoxylon)IBA
08/2013
1Lewis Y antigenIBA
04/2013
1Proteins (Proteins, Gene)FDA Link
04/2013
1procaine isothiocyanate (PRIT)IBA
03/2013
1Lysine (L-Lysine)FDA Link
12/2011
1AvidinIBA
12/2011
1N 30IBA
06/2010
1Trastuzumab (Herceptin)FDA Link
10/2007

Therapy/Procedure

18Radioimmunotherapy
02/2020 - 09/2003
13Therapeutics
02/2020 - 07/2009
8Aftercare (After-Treatment)
02/2020 - 11/2005
3Drug Therapy (Chemotherapy)
01/2019 - 07/2009
2Intravenous Injections
01/2021 - 01/2017
2Catheters
01/2019 - 07/2009
1Castration
02/2020
1Transcutaneous Electric Nerve Stimulation (TENS)
08/2013